In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $36.17, marking a -5.51% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.45%.

Learn more Leerink maintained a 'Market Perform' rating and a $25 price target, implying a 10% downside from current levels. The brokerage flagged uncertainty around future profits from branded GLP-1 ...

Hims & Hers Health, Inc. (HIMS) closed at $31.89 in the latest trading session, marking a +1.33% move from the prior day. This change outpaced the S&P 500's 1.22% loss on the day. On the other hand, ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Photo illustration of Wegovy and a weight scale. Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, saw its stock surge 8% on Friday, May 30th, following the announcement of a 4% workforce reduction. This adjustment comes as the company adapts ...

Throughout 2024, Hims & Hers demonstrated consistent top-line acceleration driven by new product introductions and broader consumer adoption. The company’s revenue grew from $260 million in Q1 2024 to ...

One prioritizes rapid consumer growth and profitability; the other commands scale but faces concentration risk.